The 18th International Conference on Endothelin, co-organized by the International Advisory Board (IAB) on Endothelin and the Fondazione Internazionale Menarini, was held in Rome, Italy, on October 11th-14th, 2023. More than 100 attendees from all over the world participated in the conference, including trainees, early-career and established investigators from several European countries (Italy, France, Switzerland, Sweden, the Netherlands, Belgium, the United Kingdom (UK), Germany, the Czech Republic), USA, Canada, Japan, Australia, Brazil, China, Taiwan, and Indonesia.

The 3 days of the conference were introduced by an opening lecture of Anthony Davenport of the University of Cambridge, UK, on recent advances in drugs acting on the endothelin system, and featured 8 thematic sessions (Oncology; Hypertension; Neurology; Nephrology; Cardiology; Endocrinology and Metabolism; Pneumology and Rheumatology; Dermatology and Women's Health). Each thematic session was opened by a keynote lecture and closed by an invited lecture by renowned authorities in the endothelin field, and also included presentations selected according to the grading of submitted abstracts. The program included also two moderated e-poster sessions, where the results of recent studies (mostly performed by early-career scientists) were presented. As a tradition of this series of conference (held every 2 years), the most relevant novelties were summarized at the end of the meeting in a “wrap-up” by the scientist who discovered endothelin in 1988, Masashi Yanagisawa of the University of Tsukuba, Japan.

Because of the commitment of the IAB to foster the research efforts in the endothelin field of new generations of scientists, 24 Young Investigator Awards were assigned to those investigators younger than 40 who had an abstract accepted either as an oral or e-poster presentation, to support their travel and lodging expenses.

The conference covered novel pathophysiological aspects of endothelin signaling, ranging from tumor growth to facio-cranial abnormalities, neurodegenerative disorders and hair follicle remodeling. Of note, the conference discussed the results of recently-concluded and ongoing clinical trials, especially in kidney disease, ischemic stroke and resistant hypertension, which are filling the translational gap and expanding the clinical indications of endothelin-based therapies.

At the end of the conference, the Chair of the local organizing committee announced the forthcoming 19th International Conference on Endothelin, which will be held in the United States in 2025.

Thanks to the interest and commitment of its editor-in-chief, Michael Ryan, Clinical Science is publishing the abstract of the conference and a collection of articles dedicated to endothelin.